Bayer folate campaign to star TV's Minnillo

Share this article:
Bayer HealthCare Pharmaceuticals, maker of the folate-enhanced contraceptives Safyral and Beyaz, has recruited TV personality Vanessa Minnillo to front an unbranded campaign promoting the use of daily folate supplements to women.

The Girlfriends for Folate campaign, for which the company has partnered with the March of Dimes and women's website, features a Facebook page and a competition inviting women to register with the site as a “GFF.” Bayer will donate $1 to the March of Dimes for every registration, and the winning region will host a celebrity walk, including Minnillo, the weekend of April 30. Registrants can also pitch in on fundraising, and the company will fly out the top fundraiser to walk with Minnillo.

Bayer won approval for two oral contraceptives last year – Safyral and Beyaz – that are similar to its Yasmin and Yaz, plus folate and a B vitamin. The contraceptives are indicated for boosting folate, thereby reducing the risk of serious birth defects, known as neural tube defects, in a pregnancy conceived while taking the product or shortly thereafter. In announcing Beyaz's approval, Bayer quoted Dr. Anita Nelson, professor of obstetrics and gynecology at the Harbor-UCLA Medical Center, Torrance, California as saying: “Combining an oral contraceptive with folate is important, because women may become pregnant during OC use or shortly after discontinuation, possibly before seeking preconception counseling from their healthcare provider. For women who want to use an oral contraceptive, Beyaz offers a new option for women to receive daily folate supplementation.”
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...